A Phase I, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of APL-2
Phase of Trial: Phase I
Latest Information Update: 31 May 2018
At a glance
- Drugs APL 2 (Primary)
- Indications Dry age-related macular degeneration; Ischaemia; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration
- Focus Pharmacokinetics
- Acronyms AIRIS
- 30 May 2018 Status changed from recruiting to completed.
- 20 Oct 2017 Planned initiation date changed from 11 Jul 2017 to 15 Sep 2017.
- 20 Oct 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.